Aetna · Identified Aug 19, 2026Medium impact
Lung Transplantation (CPB 0598, reviewed 2025-12-02)
Aetna considers lung transplantation medically necessary for qualifying conditions, including cystic fibrosis, emphysema including alpha-1-antitrypsin deficiency, pulmonary fibrosis, pulmonary hypertension, Eisenmenger's complex, sarcoidosis, lymphangioleiomyomatosis, bronchopulmonary dysplasia and graft-versus-host disease, for members who meet the transplanting institution's selection criteria or, where there are none, the general and disease-specific selection criteria. Lung transplantation is considered not medically necessary for contraindications including lung malignancy, multi-system disease, acute or chronic active infection not adequately treated, and smoking, since members with a history of smoking must be abstinent for 6 months before being considered eligible. Lobar lung transplantation, anti-thymocyte globulin for acute cellular rejection and ex vivo lung perfusion for preservation and transplant of donor lungs are considered medically necessary, while AlloSure, Prospera Lung and lung xenotransplantation are considered experimental, investigational or unproven.